Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer
Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Hou...
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer ( Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas )
19 Sep 2021
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-ne...
Prof Hope Rugo - University of California San Francisco, San Francisco, USA
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )
19 Sep 2021
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple mye...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )
19 Sep 2021
Impact of cytogenetic abnormalities on treatment outcomes in patients with AL am...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
19 Sep 2021
FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-l...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of unresectable mCRC patients ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
18 Sep 2021
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trast...
Prof Nadia Harbeck - University of Munich, Munich, Germany
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )
18 Sep 2021
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advan...
Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )
18 Sep 2021
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone recept...
Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )
18 Sep 2021
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed...
Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, U...
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )
18 Sep 2021
MRD-guided therapy debate
Prof Ola Landgren - University of Miami, Miami, USA
MRD-guided therapy debate ( Prof Ola Landgren - University of Miami, Miami, USA )
18 Sep 2021
KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resecte...
Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA
KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma ( Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA )
18 Sep 2021
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical ...
Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer ( Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA )
18 Sep 2021